We acquired exclusive rights to develop, produce and commercialize two new analgesic drugs, RMX1001 and RMX1002, from HaiHe Biopharma in China.

We signed a collaboration agreement with Beijing University of Chinese Medicine to develop and market the national Class I innovative drug with Lei Haimin's team at the School of Chinese Medicine in 2015.

We signed a collaboration intention with Alphamab for the global collaborative development of KN035 in 2016.

- In 2017, we initiated the KN035 clinical trial for first patient dosing in the U.S. The first patient in China was dosed in March and Phase I clinical trial in Japan was started in August.

- Initiated research and development of 3D011 with PCT patent application filed globally. 

- 3D Medicines spilt into 3D Medicines Inc. and 3D Diagnostics in 2018.

- We were granted the exclusive global development license for HaiHe Biopharma’s 3D185 in the fields of Cancer and Pulmonary Fibrosis.

We initiated registered clinical trials of KN035 in North America.

In January, 2020, KN035 was awarded Orphan Drug Designation by FDA.

In March, 2020, a partnership with Alphamab and Simcere Pharmaceuticals was formed for the development and commercialization of KN035 in China.

- In September, 2020, we reached a strategic collaboration agreement with GenScriptProBio for discovery of biologics.

- In September, 2020, KN035 was granted priority review by CDE.

- In October, 2020, we received $140 million investment from Simcere Pharmaceuticals, Efung Capital, China Capital Management and other institutions.

- In October, 2020, a new laboratory building for Translational Medicine Center came into service, and R&D capabilities continued to grow.

- In October, 2020, we signed a strategic collaboration agreement with XtalPi for drug discovery.

- In October, 2020, we acquired exclusive rights to develop, manufacture, and commercialize two new analgesic molecules, RMX1001 and RMX1002, from HaiHe Biopharma in China.

- In November, 2020, We were authorized by Aravive to exclusively develop and commercialize AVB-500, a new anti-cancer drug, in Greater China.

- In November, 2020, Envafolimab (KN035), the world's first PD-L1 antibody drug given via subcutaneous Injection submitted new drug application for marketing in China.

- In December, 2020, we acquired exclusive rights for a new immuno-oncology drug in Phase 3 clinical trials in Greater China.

- In December, 2020, the NDA of Envafolimab (KN035) was officially accepted by the NMPA.

In January, 2021, we signed license agreement with Y-Biologics on the co-development of next-generation T cell bispecific engager.